EP0903146A1 — 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
Assigned to Applied Research Systems ARS Holding NV · Expires 1999-03-24 · 27y expired
What this patent protects
The conformationally highly bent steroid 21-hydroxy-6,19- oxidoprogesterone (21OH- 6OP) has been found to be a selective antiglucocorticoid virtually lacking mineralococortioid or glucocorticoid properties as well as affinity for MR or PR and is used for the treatment of diseases…
USPTO Abstract
The conformationally highly bent steroid 21-hydroxy-6,19- oxidoprogesterone (21OH- 6OP) has been found to be a selective antiglucocorticoid virtually lacking mineralococortioid or glucocorticoid properties as well as affinity for MR or PR and is used for the treatment of diseases associated with an excess of glucocorticoids in the body, such as the Cushing's syndrome or depression.
Drugs covered by this patent
- Mifeprex (MIFEPRISTONE) · Corcept Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.